Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89Bio Inc
(NQ:
ETNB
)
8.855
+0.385 (+4.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 89Bio Inc
< Previous
1
2
3
4
5
6
7
Next >
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
89bio, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for 89bio
September 22, 2023
Via
Benzinga
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
September 21, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023
From
89bio, Inc.
Via
GlobeNewswire
Analyst Ratings for 89bio
August 10, 2023
Via
Benzinga
BTIG Maintains Buy Rating for 89bio: Here's What You Need To Know
July 03, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About 89bio
July 03, 2023
Via
Benzinga
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
89bio, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
August 28, 2023
Via
Benzinga
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
89bio, Inc.
Via
GlobeNewswire
Analyst Ratings for 89bio
May 08, 2023
Via
Benzinga
3 Biotech Buyout Targets to Watch
April 29, 2023
The trio all have late-stage therapies with blockbuster potential.
Via
The Motley Fool
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/19
April 19, 2023
Via
Investor Brand Network
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2023
From
89bio, Inc.
Via
GlobeNewswire
Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
July 03, 2023
Jefferies boosted the price target for ACM Research, Inc. (NASDAQ: ACMR) from $9 to $23.4. Jefferies analyst Nick Cheng upgraded the stock from Underperform to Buy. ACM Research shares fell 2.2% to...
Via
Benzinga
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
June 24, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/10
April 10, 2023
Via
Investor Brand Network
89Bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 3/31
March 31, 2023
Via
Investor Brand Network
Over $40M Bet On 89bio? Check Out These 3 Stocks Insiders Are Buying
March 31, 2023
Although US stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
June 24, 2023
From
89bio, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
June 13, 2023
Via
Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
89Bio Inc. (NASDAQ: ETNB) Records 52-Week High Friday Morning
March 24, 2023
Via
Investor Brand Network
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
June 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
May 23, 2023
First FGF21 analog to enter Phase 3 development
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
Why Shares of 89bio Soared This Week
March 24, 2023
The company released positive results for its lead therapy.
Via
The Motley Fool
89bio to Participate in Upcoming Investor Conferences
May 02, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
March 24, 2023
From
89bio, Inc.
Via
GlobeNewswire
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 23, 2023
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.